ESOPHAGEAL ADENOCARCINOMA

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation helps people with advanced esophageal cancer. About 42 adults with cancer that had not spread to other organs took part. The main goal was to see if the combination improv…

This study tests whether a new drug called zanidatamab, given with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for advanced HER2-positive stomach and esophageal cancer. About 920 adults whose cancer has spread or cannot…

This study is for people with HER2-positive esophageal or stomach cancer who have finished chemoradiation and surgery but still had some cancer cells left. It tests whether a year-long combination of two drugs, trastuzumab deruxtecan (Enhertu) and nivolumab, can safely prevent th…

This study tests the safety of adding the drug durvalumab to standard chemoradiation for people with esophageal or gastroesophageal junction cancer. About 64 participants will receive initial chemotherapy followed by chemoradiation plus durvalumab. The goal is to see if this comb…

This study tests whether adding the drug tucatinib to standard treatments (like trastuzumab and chemotherapy) is safe for people with HER2-positive cancers of the digestive system. About 40 adults with advanced cancer of the colon, stomach, esophagus, or gallbladder will receive …

This study tests whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer. About 278 adults with stage II to IVA cancer will receive the combination before and after s…

This study tests whether adjusting chemotherapy doses based on a patient's genetics can improve outcomes for people with advanced stomach or esophageal cancer that has spread to nearby tissues or lymph nodes. About 36 participants will receive a chemotherapy regimen called mFOLFI…

This study tests a new combination of drugs (futibatinib plus a PD-1 antibody) in adults with advanced esophageal or pancreatic cancer that cannot be removed by surgery. The goal is to see if the combo shrinks tumors and is safe. About 53 people will take part, and they must not …

This study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…

This study explores whether a device called Endosign, which collects samples from the mouth, can reliably monitor Barrett's esophagus—a condition that can lead to esophageal cancer. Current monitoring requires regular, uncomfortable endoscopies. The study involves 60 adults with …

This study tests a simple, less invasive screening tool—a sponge on a string—to detect Barrett's esophagus and esophageal cancer. Researchers will enroll 450 adults with Barrett's esophagus who are already scheduled for an endoscopy. The goal is to see if DNA markers from the spo…

This early-phase study tests whether taking aspirin can prevent Barrett's esophagus from returning after it has been successfully removed with a procedure called radiofrequency ablation. About 21 participants will take either aspirin or a placebo for 12 months, and researchers wi…